Drug intelligence / Profile preview

SCT-520FF

Development stage: Phase 2
Lead developer: Sinocelltech
Modality: Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

SCT-520FF is a Fab fragment biologic drug that acts as an inhibitor of vascular endothelial growth factor A (VEGF-A). It is being developed primarily for the treatment of neovascular (wet) age-related macular degeneration (nAMD), a condition characterized by abnormal blood vessel growth in the retina leading to vision loss. The drug’s mechanism involves blocking VEGF-A, thereby inhibiting angiogenesis and reducing pathological blood vessel formation in the eye. SCT-520FF was initially developed by Sinocelltech Group and is currently in Phase 1/2 clinical trials, with Shenzhou Cell Engineering also involved in its development and manufacturing[1][4][5].

Other names: VEGF Fab

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on SCT-520FF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCT-520FF.

Explore the full profile